SCHEMBL2290164

SCHEMBL2290164

O=C(Nc1ccccc1C(=O)O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.76
NPC1 O15118 4/20 0.76
RAB9A P51151 4/20 0.76
MEN1 O00255 4/20 0.76
KMT2A Q03164 4/20 0.76
SENP7 Q9BQF6 2/20 0.74
CASP3 P42574 1/20 0.74
TAAR1 Q96RJ0 1/20 0.74
PLK1 P53350 1/20 0.67
NR4A1 P22736 1/20 0.63
NR4A2 P43354 1/20 0.63
NR4A3 Q92570 1/20 0.63
NR1H4 Q96RI1 1/20 0.63
DHODH Q02127 1/20 0.62
RXFP1 Q9HBX9 1/20 0.62
MAPK1 P28482 1/20 0.61
HSD17B10 Q99714 1/20 0.61
HDAC1 Q13547 3/20 0.60
HDAC3 O15379 2/20 0.60
HDAC2 Q92769 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2295551 0.91 NPC1 (0.71) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL2291513 0.88 KDM4E (0.69) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL2275173 0.86 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL27741786 0.85 NPC1 (0.72) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6338190 0.85 KDM4E (0.66) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6351828 0.85 PTGES (0.62) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL8041182 0.84 PLK1 (0.68) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL6577738 0.84 NPC1 (0.63) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL2025586 0.84 MEN1 (0.72) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL30466712 0.84 MEN1 (0.72) SMN1; SMN2NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101193853-B Anthranilic acid derivatives HOFFMANN LA ROCHE 2011-11-23 CN claimed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US claimed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US claimed
JP-2008546661-A 2008-12-25 JP claimed
CN-101193853-A Anthranilic acid derivatives HOFFMANN LA ROCHE (CH) 2008-06-04 CN claimed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP claimed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO claimed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US claimed
CN-101193853-B Anthranilic acid derivatives HOFFMANN LA ROCHE 2011-11-23 CN disclosed
US-7989657-B2 Anthranilic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-02 US disclosed
US-20090247637-A1 Novel Anthranilic Acid Derivatives DEHMLOW HENRIETTA 2009-10-01 US disclosed
CN-101193853-A Anthranilic acid derivatives HOFFMANN LA ROCHE (CH) 2008-06-04 CN disclosed
EP-1896396-A1 ANTHRANILIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-03-12 EP disclosed
WO-2006134040-A1 ANTHRANILIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-21 WO disclosed
US-20060281810-A1 Novel anthranilic acid derivatives HOFFMANN-LA ROCHE INC. 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281810-A1 Novel anthranilic acid derivatives GPR84, HCAR1, GPR88 SMN1; SMN2 3830/4885NPC1 3594/4885RAB9A 1353/4885
US-20090247637-A1 Novel Anthranilic Acid Derivatives GPR84, GPR88, HCAR1 SMN1; SMN2 3904/4885NPC1 3210/4885RAB9A 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.